Ibrahim Khormi1,2,3, Oun Al-iedani2,4, Stefano Casagranda5, Christos Papageorgakis5, Abdulaziz Alshehri1,2,6, Rodney Lea2, Patrick Liebig7, Saadallah Ramadan1,2, and Jeannette Lechner-Scott2,8,9
1School of Health Sciences, University of Newcastle, Callaghan, Australia, 2Hunter Medical Research Institute, New Lambton Heights, Australia, 3College of Applied Medical Sciences, University of Jeddah, Jeddah, Saudi Arabia, 4School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia, 5Department of R&D Advanced Applications, Olea Medical, La Ciotat, France, 6Department of Radiology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Al Khobar, Saudi Arabia, 7Siemens Healthineers, Erlangen, Germany, 8School of Medicine and Public Health, University of Newcastle, New Lambton Heights, Australia, 9Department of Neurology, John Hunter Hospital, New Lambton Heights, Australia
Synopsis
Keywords: CEST / APT / NOE, Multiple Sclerosis
Motivation: Monitoring disease progression in people with relapsing-remitting multiple sclerosis (pw-RRMS) presents a substantial clinical challenge. Conventional MRI often fails to provide molecular biomarkers for pathophysiological changes like myelin protein accumulation indicative of demyelination.
Goal(s): The study aimed to validate whether amide proton transfer weighted (APTw) imaging could be a sensitive molecular marker for detecting demyelination in MS lesions.
Approach: We conducted APTw imaging at 3T on 24 pw-RRMS, evaluating the signal intensity within MS lesions compared to contralateral normal-appearing white matter (cNAWM) regions.
Results: The investigation revealed a statistically significant increase in APTw signal intensity in MS lesions compared to cNAWM regions.
Impact: Elevated APTw signal intensity could serve as a
non-invasive molecular biomarker for demyelination, potentially aiding in the
more accurate monitoring of MS disease progression and treatment efficacy.
Introduction
Multiple Sclerosis (MS) is a chronic
neurodegenerative disease whose diagnosis and monitoring relies on conventional
MRI1. Unfortunately, the MRI biomarkers of MS are
not unique to its pathophysiological substrates 2.
Autoimmune attacks in MS disease cause inflammatory demyelination, leading to
axonal loss and destruction of myelin. Axonal loss and demyelination in MS lead
to the breakdown of myelin proteins2,3.
Novel MRI techniques attempt to
unravel the biochemical changes and demyelination processes occurring in the
focal MS lesions and normal-appearing white matter (NAWM) of pw-MS. Some of
these studies have validated their MRI findings with histological results of breakdown products of myelin proteins within
macrophages/microglia in post-mortem MS brains4,5.
To gain insight into proteins involved
in demyelination in MS, amide proton transfer weighted (APTw) imaging has been
developed as an endogenous proteins contrast technique in tissue6,7.
APTw imaging is a novel advanced MRI technique capable of indirectly measuring
intra/extra-cellular proteins by detecting the chemical exchange between amide
protons of mobile proteins and water protons6,8.
This study aims to evaluate APTw
signal differences between MS lesions and contralateral normal-appearing white
matter (cNAWM). Cellular changes during the demyelination process were assessed
by comparing APTw signal intensity in T1-weighted isointense (ISO) and hypointense
(black hole-BH) lesions in relation to cNAWM.Methods
$$24 people with relapsing-remitting MS
on stable therapy were recruited (19 females and 5 males with mean age:48.11
years; mean disease duration:11.25 years; median EDSS:2). MRI/APTw acquisitions
were undertaken on 3T MRI. For assessment of MS lesions, 3D T1-MPRAGE and
T2-FLAIR were used. The
APTw sequence used a 3D snapshot-GRE. The acquisition time for APTw volumes at
two B1 values (1.8μT and 2.6μT) was 3:07 minutes for each B1 (RF
saturation with 20 Gaussian pulses with duration/interpulse delay=50/40ms, 55%
Duty Cycle, one off-resonance (300ppm) pre-saturation M0 volume and
25 APTw M( )
volumes with equally-spaced relative offsets from
-6ppm to 6ppm from water frequency). Additional WASAB1 sequence was acquired
for simultaneous B0 and B1 mapping (2:03 minutes)9.
The APTw data were denoised10,11, normalised by M0, and B0/B1 corrected
(reconstructed with B1=2.6μT)12,13. APTw map was computed around amide relative
resonance frequency offset from water (3.5ppm) using the following non-punctual
metric13:
$$$ APTw =\int_{-4ppm}^{-3ppm} Z(\triangle
\omega)\delta \omega -\int_{4ppm}^{3ppm} Z(\triangle \omega)\delta \omega
$$$
Where Z(Δω)= M (Δω)/ M0 is
the APTw-Z_Spectrum.
Pre/post-processing APTw analysis,
co-registration with structural MRI maps, and identifying regions of interest (ROI)
were all performed with Olea Sphere 3.0 software. Generalized linear model
univariate ANOVA was undertaken to test the hypotheses that differences in mean
APTw signal intensity. The mean APTw signal intensity was computed from 530 MS
lesions and 521 cNAWM ROIs. Receiver operating characteristic curve analyses
were performed to evaluate the diagnostic performance of these comparisons.Results
Mean APTw signal intensity values of
MS lesions were higher than cNAWM (lesion=0.44, cNAWM=0.13, F=44.12, p<0.001).
The mean APTw values of ISO lesions were higher than cNAWM (ISO lesions=0.42,cNAWM=0.21,F=12.12,p<0.001).
The mean APTw signal intensity values of BH were higher than cNAWM (BH
lesions=0.47, cNAWM=0.033,F=40.3,p<0.001), Table 1. The effect size
(difference between lesion and cNAWM) for BH was found to be higher than for
ISO (14 vs.2). Diagnostic performance showed that APTw was able to discriminate
between all lesions and cNAWM with an accuracy of greater than 75%
(AUC=0.79,SE=0.014). Discrimination between ISO lesions and cNAWM was
accomplished with an accuracy greater than 69% (AUC=0.74,SE=0.018), while
discrimination between BH lesions and cNAWM was achieved at an accuracy of
greater than 80% (AUC=0.87,SE=0.021), Table 2.Discussion
These results present a novel application
for assessing APTw signal across different MS lesions in RRMS. We found
significantly elevated APTw signal intensity in MS lesions compared to cNAWM
regions. These findings are consistent with several studies that confirmed
higher APTw signal intensity among MS lesions6,14.
These results could be explained by the increase of mobile myelin proteins
decomposition and accumulation from the demyelination
process5,6.
In addition, the signal intensity of
BH lesions in APTw is higher than ISO lesions when compared to their respective
regions of cNAWM, Figure 1. Gadolinium-free APTw maps could help identify
different stages and characteristics of MS that depend on the demyelination
status of the various lesion types and stages. APTw imaging has the potential
to provide an advantage over FLAIR hyper signal in detecting and characterizing
MS lesions.Conclusion
The APTw technique is novel and has
the potential to be a useful and sensitive tool for investigating the
pathophysiology of MS. Increasing APTw signal intensity in MS lesions supports
MS post-mortem histological results. Gadolinium-free APTw contrast mechanism
provides promising insight into pathologies on a molecular level.Acknowledgements
-
This
research was kindly supported by MS Research Australia.
- The
authors acknowledge the facilities and scientific and technical
assistance
of the National Imaging Facility, a National Collaborative
Research
Infrastructure Strategy (NCRIS) capability, at the Hunter
Medical
Research Institute Imaging Center, University of Newcastle.
- We
thank Dr. Scott Quadrelli, the neuroradiologist who provided valuable advice on
identification of MS lesions and sub-categorizing them into two groups.
- We
thank the RELIEF staff and investigator teams, and the participants involved.
- Ibrahim Khormi was supported by a PhD scholarship from University of Jeddah, Saudi
Arabia.
References
1. Weidauer S, Raab P, Hattingen E. Diagnostic approach in multiple sclerosis with MRI: an update. Clinical Imaging 2021.
2. Weil MT, Mobius W, Winkler A, et al. Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases. Cell Rep 2016;16(2):314-322.
3. Lubetzki C, Stankoff B. Demyelination in multiple sclerosis. Handbook of clinical neurology. Volume 122: Elsevier; 2014. p. 89-99.
4. De Groot CJ, Bergers E, Kamphorst W, et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001;124(Pt 8):1635-1645.
5. Kuhlmann T, Ludwin S, Prat A, Antel J, Bruck W, Lassmann H. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol 2017;133(1):13-24.
6. Sartoretti E, Sartoretti T, Wyss M, et al. Amide Proton Transfer Weighted Imaging Shows Differences in Multiple Sclerosis Lesions and White Matter Hyperintensities of Presumed Vascular Origin. Front Neurol 2019;10:1307.
7. Falk Delgado A, Van Westen D, Nilsson M, et al. Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging-a comprehensive overview. Insights Imaging 2019;10(1):84.
8. Ye H, Shaghaghi M, Chen Q, et al. In Vivo Proton Exchange Rate (k(ex) ) MRI for the Characterization of Multiple Sclerosis Lesions in Patients. J Magn Reson Imaging 2021;53(2):408-415.
9. Schuenke P, Windschuh J, Roeloffs V, Ladd ME, Bachert P, Zaiss M. Simultaneous mapping of water shift and B(1) (WASABI)-Application to field-Inhomogeneity correction of CEST MRI data. Magn Reson Med 2017;77(2):571-580.
10. Buckheit J, Chen S, Donoho D, Johnstone I, Scargle J. About wavelab. Handbook of WaveLab Version 1995;850:1-37.
11. Breitling J, Deshmane A, Goerke S, et al. Adaptive denoising for chemical exchange saturation transfer MR imaging. NMR in Biomedicine 2019;32(11):e4133.
12. Windschuh J, Zaiss M, Meissner JE, et al. Correction of B1âinhomogeneities for relaxationâcompensated CEST imaging at 7 T. NMR in biomedicine 2015;28(5):529-537.
13. Papageorgakis C, Firippi E, Gy B, et al. CEST 2022–Fast WASABI post-processing: Access to rapid B0 and B1 correction in clinical routine for CEST MRI. Magnetic Resonance Imaging 2023.
14. Dula AN, Asche EM, Landman BA, et al. Development of chemical exchange saturation transfer at 7 T. Magn Reson Med 2011;66(3):831-838.